Fundraising Fox
/Companies
Sign in

BioSig Technologies

NASDAQ: STEX

Los Angeles, US · Founded 2011 · Delaware corporation

Find your way into BioSig Technologies

60 people in our graph share verified history with the BioSig Technologies team — schools, employers, funds. One of them is your warm intro.

Curry Robertsunlockedknows Steve Chaussy · together at Virginia Tech (overlapped)
×6knows the team · via Virginia Tech
knows the team · via Penske Truck Leasing
knows the team · via Mesa Laboratories, Inc.
×3knows the team · via Lafayette College

Streamex Corp. operates a blockchain-based platform for tokenizing real-world assets, beginning with GLDY, a digital token backed by physical gold held in a Cayman Islands special purpose vehicle with yield generated through gold leasing; the company also maintains a legacy medical device business developing advanced signal processing software for cardiac electrophysiology applications.

BiotechHealthtech

Founders & leadership

BioSig Technologies was founded in 2011 by Kenneth L. Londoner.

KLKenneth L. Londoner
Kenneth L. LondonerChairman and Chief Executive OfficerKenneth L. Londoner founded BioSig Technologies in 2009 and has held executive roles including executive vice president at NewCardio, a cardiac software company, and managing partner of Endicott Management Partners, which advises emerging growth companies on corporate development and investment matters.
FG
Ferdinand GroenewaldChief Financial Officer
AAAnthony Amato
Anthony AmatoChief Executive OfficerAnthony Amato is Chief Executive Officer of BioSig Technologies, which develops signal processing software for cardiac electrophysiology applications.
MG
Michael Graydon Fleming, Jr.Chief Commercial Officer
JS
John SieckhausChief Operating Officer
SJ
Steven J BuhalyChief Financial Officer
SC
Steve ChaussyChief Financial OfficerSteve Chaussy is Chief Financial Officer of BioSig Technologies, which develops signal processing software for cardiac electrophysiology applications. He has experience in the medical device industry with background in tax preparation, cash flow management, and business planning.

Board

SE
Steven E. AbelmanBoard director
FD
Frederick D. HrkacBoard director
CB
Chris BaerBoard director
DF
Donald F. BrowneBoard director
JJ
James J. BarryBoard director

Reported raises · per SEC filings

Form D private placements

$61.1M disclosed across 36 of 37 rounds · 2013–2025

▶$819KraisedMar 2025 · 11 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven E. AbelmanDirector
  • Ferdinand GroenewaldExecutive Officer
  • Frederick D. HrkacDirector
  • Anthony AmatoExecutive Officer, Director
  • Chris BaerDirector
  • Donald F. BrowneDirector
Offering amount
$819K
Amount sold
$819K
First sale
Mar 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedJun 2024 · 4 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Anthony AmatoExecutive Officer, Director
  • Frederick D. HrkacExecutive Officer, Director
  • Donald F. BrowneDirector
  • Steven E. AbelmanDirector
  • Chris BaerDirector
Offering amount
$3M
Amount sold
$3M
Sales commissions
$240K
Placement agents
H.C. Wainwright & Co.
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedJun 2024 · 6 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven E. AbelmanDirector
  • Frederick D. HrkacExecutive Officer
  • Chris BaerDirector
  • Donald F. BrowneDirector
  • Anthony AmatoExecutive Officer, Director
Offering amount
$1.1M
Amount sold
$1.1M
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedJan 2024 · 7 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • John SieckhausExecutive Officer
  • James J. BarryDirector
  • Frederick D. HrkacDirector
  • David Weild IVDirector
  • Donald E. FoleyDirector
  • James L. KleinDirector
  • Patrick J. GallagherDirector
  • Kenneth L. LondonerExecutive Officer, Director
  • Michael Graydon Fleming, Jr.Executive Officer
  • Steven J BuhalyExecutive Officer
Offering amount
$1.5M
Amount sold
$1.5M
First sale
Jan 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$860.9KraisedOct 2023 · 20 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • David Weild IVDirector
  • Frederick D. HrkacDirector
  • Kenneth L. LondonerExecutive Officer, Director
  • Patrick J. GallagherDirector
  • Michael Graydon Fleming, Jr.Executive Officer
  • John SieckhausExecutive Officer
  • Donald E. FoleyDirector
  • Steven J BuhalyExecutive Officer
  • James J. BarryDirector
  • James L. KleinDirector
Offering amount
$860.9K
Amount sold
$860.9K
Sales commissions
$59.8K
Placement agents
Laidlaw & Company (UK) Ltd.
First sale
Oct 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedOct 2023 · 10 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven J BuhalyExecutive Officer
  • Frederick D. HrkacDirector
  • Michael Graydon Fleming, Jr.Executive Officer
  • James J. BarryDirector
  • Kenneth L. LondonerExecutive Officer, Director
  • Patrick J. GallagherDirector
  • Donald E. FoleyDirector
  • John SieckhausExecutive Officer
  • James L. KleinDirector
  • David Weild IVDirector
Offering amount
$1.2M
Amount sold
$1.2M
Sales commissions
$30K
Placement agents
Laidlaw & Company (UK) Ltd.
First sale
Sep 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$794KraisedSep 2023 · 4 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • John SieckhausExecutive Officer
  • Steven J BuhalyExecutive Officer
  • James J. BarryDirector
  • Kenneth L. LondonerExecutive Officer, Director
  • Frederick D. HrkacDirector
  • James L. KleinDirector
  • Donald E. FoleyDirector
  • Patrick J. GallagherDirector
  • David Weild IVDirector
  • Michael Graydon Fleming, Jr.Executive Officer
Offering amount
$794K
Amount sold
$794K
Sales commissions
$53K
Placement agents
Laidlaw & Company (UK) Ltd.
First sale
Sep 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.2MraisedAug 2023 · 1 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Donald E. FoleyDirector
  • Kenneth L. LondonerExecutive Officer, Director
  • John SieckhausExecutive Officer
  • Steven J BuhalyExecutive Officer
  • James J. BarryDirector
  • Patrick J. GallagherDirector
  • Michael Graydon Fleming, Jr.Executive Officer
  • James L. KleinDirector
  • David Weild IVDirector
  • Frederick D. HrkacDirector
Offering amount
$2.2M
Amount sold
$2.2M
Sales commissions
$150K
Placement agents
Laidlaw & Company (UK) Ltd.
First sale
Jul 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

BioSig Technologies shareholders approve share increase and board changes By Investing.cominvesting.com · Sep 2025$15M Raised: BioSig's Strategic Move into Gold Tokenization Infrastructure After Streamex Mergerstocktitan.net · Aug 2025BioSig Technologies raises $15 million in public offering By Investing.cominvesting.com · Aug 2025BioSig Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1.1B USD in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand RWA Tokenization for the Commodities Marketsbusinesswire.com · Jul 2025ascendiant capital raises biosig technologies stock price target By Investing.cominvesting.com · Jun 2025BioSig's NeuroClear Technologies raises nearly $4m - MassDevicemassdevice.com · Sep 2019

Frequently asked questions

What does BioSig Technologies do?
Streamex Corp. operates a blockchain-based platform for tokenizing real-world assets, beginning with GLDY, a digital token backed by physical gold held in a Cayman Islands special purpose vehicle with yield generated through gold leasing; the company also maintains a legacy medical device business developing advanced signal processing software for cardiac electrophysiology applications.
Who founded BioSig Technologies?
BioSig Technologies was founded by Kenneth L. Londoner in 2011.
How much funding has BioSig Technologies raised?
BioSig Technologies has disclosed $61.1M raised across 36 of its 37 known rounds.
Where is BioSig Technologies headquartered?
BioSig Technologies is headquartered in Los Angeles, US.